Journal of Neural Transmission

, Volume 121, Issue 4, pp 357–366

Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

  • Eduardo Tolosa
  • Basilio Hernández
  • Gurutz Linazasoro
  • Juan José López-Lozano
  • Pablo Mir
  • José Marey
  • Jaime Kulisevsky
Neurology and Preclinical Neurological Studies - Original Article


To compare the efficacy and safety of levodopa/carbidopa/entacapone (LCE) with levodopa/carbidopa (LC) on Parkinson’s disease (PD) patients with mild, or only minimally disabling motor complications. A prospective 3-month, multicentre, parallel-group, double-blind, and randomised phase IV study was performed. The primary endpoint was to assess the efficacy of LCE compared to LC on ADLs using the UPDRS part II. Secondary endpoints were assessed by the UPDRS (I, III and IV) scores, QUICK and PDQ-39 questionnaires, and patient and investigator clinical global impression (CGI). Ninety-five patients were randomly assigned to treatment with LCE (100/25/200 or 150/37.5/200 mg tablets, n = 46) or LC (100/25 mg tablets, n = 49), at the same levodopa dose that were administered before randomization. Treatment with LCE resulted in significantly greater improvement in UPDRS part II (ADLs) scores compared to treatment with LC (adjusted mean difference between groups of −1.5 points) (p = 0.0288). Amelioration was also observed in UPDRS part III scores (p = 0.010), and CGI (patient and investigator) scores (p = 0.015, and p = 0.028, respectively). LCE and LC were generally well tolerated with 78 % of subjects completing the study. Most AEs (50 % in LCE and 71.4 % in LC) were classified as mild. No serious AEs were related to the treatment. Treatment with LCE results in improved efficacy compared to LC in PD patients with mild, or minimally disabling motor fluctuations, maintaining a good safety and tolerability profile.


Parkinson disease Wearing-off UPDRS Quick questionnaire 


  1. Boiko AN, Batysheva TT, Minaeva NG et al (2008) Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson’s disease in out-patient clinical practice (the START-M open trial). Neurosci Behav Physiol 38:933–936PubMedCrossRefGoogle Scholar
  2. Brooks DJ (2008) Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4:39–47PubMedCentralPubMedCrossRefGoogle Scholar
  3. Eggert K, Skogar O, Amar K et al (2010) Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study. J Neural Transm 117:333–342PubMedCrossRefGoogle Scholar
  4. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):IV37–IV42PubMedGoogle Scholar
  5. Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508PubMedCrossRefGoogle Scholar
  6. Fung VS, Herawati L, Wan Y (2009) Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord 24:25–31PubMedCrossRefGoogle Scholar
  7. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone—a review. J Neural Transm 111:1343–1363PubMedCrossRefGoogle Scholar
  8. Hauser RA, Panisset M, Abbruzzese G et al (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord 24:541–550PubMedCrossRefGoogle Scholar
  9. Larsen JP, Worm-Petersen J, Siden A et al (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 10:137–146PubMedCrossRefGoogle Scholar
  10. Martinez-Martin P, Tolosa E, Hernandez B et al (2008) Validation of the “QUICK” questionnaire–a tool for diagnosis of “wearing-off” in patients with Parkinson’s disease. Mov Disord 23:830–836PubMedCrossRefGoogle Scholar
  11. Nutt JG, Woodward WR, Beckner RM et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913–919PubMedCrossRefGoogle Scholar
  12. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 42:747–755CrossRefGoogle Scholar
  13. Piccini P, Brooks DJ, Korpela K et al (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry 68:589–594PubMedCentralPubMedCrossRefGoogle Scholar
  14. Reichmann H, Boas J, Macmahon D et al (2005) Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111:21–28PubMedCrossRefGoogle Scholar
  15. Rinne UK, Larsen JP, Siden A et al (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51:1309–1314PubMedCrossRefGoogle Scholar
  16. Ruottinen HM, Rinne UK (1998) COMT inhibition in the treatment of Parkinson’s disease. J Neurol 245:P25–P34PubMedCrossRefGoogle Scholar
  17. Schrag A (2005) Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 4:366–370PubMedCrossRefGoogle Scholar
  18. Solla P, Cannas A, Marrosu F et al (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat 6:483–490PubMedCentralPubMedCrossRefGoogle Scholar
  19. Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother 7:1399–1407PubMedCrossRefGoogle Scholar
  20. Stocchi F, Jenner P, Obeso JA (2010a) When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol 63:257–266PubMedCrossRefGoogle Scholar
  21. Stocchi F, Rascol O, Kieburtz K et al (2010b) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27PubMedCrossRefGoogle Scholar
  22. Yahr MD, Duvoisin RC, Schear MJ et al (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21:343–354PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Eduardo Tolosa
    • 1
  • Basilio Hernández
    • 2
  • Gurutz Linazasoro
    • 3
  • Juan José López-Lozano
    • 4
  • Pablo Mir
    • 5
    • 6
  • José Marey
    • 7
  • Jaime Kulisevsky
    • 8
  1. 1.Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPSUniversitat de BarcelonaBarcelonaSpain
  2. 2.Novartis FarmacéuticaBarcelonaSpain
  3. 3.Policlínica GipuzkoaSan SebastiánSpain
  4. 4.Clínica RuberMadridSpain
  5. 5.Hospital Virgen del RocíoSevillaSpain
  6. 6.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNEDBarcelonaSpain
  7. 7.Hospital Universitario A CoruñaCoruñaSpain
  8. 8.Hospital de Sant PauBarcelonaSpain

Personalised recommendations